How to buy Denali Therapeutics stock - 13 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Denali Therapeutics stock

Own Denali Therapeutics stock in just a few minutes.

Denali Therapeutics Inc is a biotechnology business based in the US. Denali Therapeutics shares (DNLI) are listed on the NASDAQ and all prices are listed in US Dollars. Denali Therapeutics employs 291 staff and has a trailing 12-month revenue of around USD$335.7 million.

How to buy shares in Denali Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Denali Therapeutics. Find the stock by name or ticker symbol: DNLI. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Denali Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Denali Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Denali Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Denali Therapeutics share price

Use our graph to track the performance of DNLI stocks over time.

Denali Therapeutics shares at a glance

Information last updated 2021-04-08.
52-week rangeUSD$18.45 - USD$93.94
50-day moving average USD$60.4277
200-day moving average USD$61.7228
Wall St. target priceUSD$81
PE ratio 83.2222
Dividend yield N/A (0%)
Earnings per share (TTM) USD$0.63

Buy Denali Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
N/A
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Gold/Commodities
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Denali Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Denali Therapeutics under- or over-valued?

Valuing Denali Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Denali Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Denali Therapeutics's P/E ratio

Denali Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 83x. In other words, Denali Therapeutics shares trade at around 83x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Denali Therapeutics's EBITDA

Denali Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$71.2 million.

The EBITDA is a measure of a Denali Therapeutics's overall financial performance and is widely used to measure a its profitability.

Denali Therapeutics financials

Revenue TTM USD$335.7 million
Operating margin TTM 18.69%
Gross profit TTM USD$123 million
Return on assets TTM 3.63%
Return on equity TTM 9.21%
Profit margin 21.19%
Book value $9.545
Market capitalisation USD$6.3 billion

TTM: trailing 12 months

Shorting Denali Therapeutics shares

There are currently 6.7 million Denali Therapeutics shares held short by investors – that's known as Denali Therapeutics's "short interest". This figure is 0.5% down from 6.7 million last month.

There are a few different ways that this level of interest in shorting Denali Therapeutics shares can be evaluated.

Denali Therapeutics's "short interest ratio" (SIR)

Denali Therapeutics's "short interest ratio" (SIR) is the quantity of Denali Therapeutics shares currently shorted divided by the average quantity of Denali Therapeutics shares traded daily (recently around 683273.56557377). Denali Therapeutics's SIR currently stands at 9.76. In other words for every 100,000 Denali Therapeutics shares traded daily on the market, roughly 9760 shares are currently held short.

However Denali Therapeutics's short interest can also be evaluated against the total number of Denali Therapeutics shares, or, against the total number of tradable Denali Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Denali Therapeutics's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Denali Therapeutics shares in existence, roughly 60 shares are currently held short) or 0.089% of the tradable shares (for every 100,000 tradable Denali Therapeutics shares, roughly 89 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Denali Therapeutics.

Find out more about how you can short Denali Therapeutics stock.

Denali Therapeutics share dividends

We're not expecting Denali Therapeutics to pay a dividend over the next 12 months.

Denali Therapeutics share price volatility

Over the last 12 months, Denali Therapeutics's shares have ranged in value from as little as $18.45 up to $93.94. A popular way to gauge a stock's volatility is its "beta".

DNLI.US volatility(beta: 1.93)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Denali Therapeutics's is 1.9303. This would suggest that Denali Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Denali Therapeutics overview

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 that has completed Phase 1b clinical trials and DNL151, which are in Phase 1 and Phase 1b clinical trials for Parkinson's disease. It is also developing receptor interacting serine/threonine protein kinase 1 (RIPK1) product candidates, such as DNL747, a selective and brain-penetrant small molecule RIPK1 inhibitor product candidate that is in Phase 1b clinical trial for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). In addition, the company develops enzyme transport vehicle: iduronate 2-sulfatase, an enzyme replacement therapy program for MPS II, a lysosomal storage disorder; antibody transport vehicle (ATV): alpha-synuclein (aSyn) program, a protein that spreads throughout the brain in Parkinson's disease; ATV: triggering receptor expressed in myeloid cells 2, a therapeutic candidate designed to rescue microglial function in Alzheimer's disease; and ATV: Tau, a therapeutic targeting the spreading of Tau. Denali Therapeutics Inc. has collaboration agreement with Takeda Pharmaceutical Company and Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, Centogene, and MedGenome Labs Private Ltd; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site